Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 35
  1. Apr 13, 2026 · 08:30 · KETA

    TripSitter Clinic Extends Lifeline via Dilutive Debt Swap as Insolvency Looms

    TripSitter Completes Debt Settlement and Announces Financing

    01
  2. Apr 13, 2026 · 08:30 · MBIO

    MindBio Therapeutics Corp.

    MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition

    02
  3. Apr 13, 2026 · 08:01 · PHRM

    PharmaTher Files Peptide Patch Patent as Stock Nears All-Time Lows Despite Pipeline Expansion

    PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

    03
  4. Apr 13, 2026 · 07:29 · SONA

    Histology Validates Prior Clinical Claims But Cash Burn Remains Critical

    Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

    04
  5. Apr 13, 2026 · 07:01 · TLT

    Theralase Preclinical Data Confirms Earlier Findings as Capital Runway Extends

    Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

    05
  6. Apr 13, 2026 · 06:30 · CHS

    CHS Shares Rally on SaaS Growth Confirmation Amid Dilution Concerns

    Comprehensive Healthcare Systems Issues CEO Shareholder Letter Highlighting Strategic Progress and Growth Outlook

    06
  7. Apr 12, 2026 · 19:30 · 4565

    Nxera Pharma Secures $22.5M Neurocrine Milestone Amidst Cash Burn Concerns

    Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

    07
  8. Apr 10, 2026 · 20:00 · LOBE

    Lobe Sciences Secures Runway with Modest Financing Amidst Strong Balance Sheet

    Lobe Sciences Ltd. Announces Non-Brokered Private Placement

    08
  9. Apr 10, 2026 · 17:42 · FNDX

    FendX Settles Debt with Equity at Discount Amidst Cash Flow Constraints

    Fendx Technologies issues 242,102 shares for debt

    09
  10. Apr 10, 2026 · 17:05 · SHRX

    Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

    Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

    10
  11. Apr 10, 2026 · 17:00 · SHRX

    Sharp Therapeutics Advances Clinical Pipeline Amidst Capital Raise and Lead Compound Optimization

    Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering

    11
  12. Apr 10, 2026 · 16:29 · BETR

    BETR-001 IND Filing Delayed to 2H 2026 as Company Extends Debt Maturity

    Betterlife issues 600,000 shares to corporate adviser

    12
  13. Apr 10, 2026 · 07:01 · TLT

    Theralase Secures Runway for Regulatory Filing Amidst Dilutive Financing

    Theralase(R) Closes $CAN 2.66 Million Financing

    13
  14. Apr 09, 2026 · 17:55 · EXE

    Extendicare Secures Investment Grade Status, Refinances Debt to Fuel Senior Care Expansion

    Extendicare Announces $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes

    14
← Newer Older →